Drug giant GSK lifts 2022 forecast again after stronger than expected quarter

Earnings were driven by high sales of the company's shingles vaccine Shingrix

Previously in July, GSK had predicted that 2022 sales would rise 6% to 8% and adjusted operating profit to climb by 13% to 15%

GSK HAS smashed analysts' estimates for third-quarter earnings, driven by higher sales of its blockbuster shingles vaccine, Shingrix.

This quarter, Shingrix blew past expectations by generating sales of €884m compared to the GSK-compiled consensus of €796m.